Clinical Trial Info

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Authored by
Staff

This is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy, safety, and immunogenicity of RSVpreF or placebo (1:1 randomization) in infants born to 10,000 healthy women vaccinated during pregnancy, as well as the safety and immunogenicity in the pregnant women.

This will be a global study that will span multiple RSV seasons.